BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sanz MA, Montesinos P. Advances in the management of coagulopathy in acute promyelocytic leukemia. Thromb Res 2020;191 Suppl 1:S63-7. [PMID: 32736781 DOI: 10.1016/S0049-3848(20)30399-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Wen J, Xu F, Zhou Q, Shi L, Liu Y, Yue J, Zhang Y, Liang X. Predictors of early death and clinical features in newly diagnosed patients with low-intermediate risk acute promyelocytic leukemia. Front Oncol 2022;12:895777. [DOI: 10.3389/fonc.2022.895777] [Reference Citation Analysis]
2 Xiao M, Zhou P, Sun K. Effect of Therapeutically Related Drugs on Coagulation-Anticoagulation Balance in Acute Promyelocytic Leukemia. Clin Appl Thromb Hemost 2022;28:10760296221080166. [PMID: 35187963 DOI: 10.1177/10760296221080166] [Reference Citation Analysis]
3 Siegal T, Benouaich-Amiel A, Bairey O. Neurologic complications of acute myeloid leukemia. Diagnostic approach and therapeutic modalities. Blood Rev 2021;:100910. [PMID: 34836656 DOI: 10.1016/j.blre.2021.100910] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
4 Tang D, Luo Y, Jiang Y, Hu P, Peng H, Wu S, Zhang G, Wang Y. LncRNA KCNQ1OT1 activated by c-Myc promotes cell proliferation via interacting with FUS to stabilize MAP3K1 in acute promyelocytic leukemia. Cell Death Dis 2021;12:795. [PMID: 34404765 DOI: 10.1038/s41419-021-04080-1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Gill H, Yung Y, Chu HT, Au WY, Yip PK, Lee E, Yim R, Lee P, Cheuk D, Ha SY, Leung RYY, Ma ESK, Kumana CR, Kwong YL. Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study. Blood Adv 2021;5:2829-38. [PMID: 34269798 DOI: 10.1182/bloodadvances.2021004789] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Wang Y, Rui Y, Shen Y, Li J, Liu P, Lu Q, Fang Y. Myeloid Sarcoma Type of Acute Promyelocytic Leukemia With a Cryptic Insertion of RARA Into FIP1L1: The Clinical Utility of NGS and Bioinformatic Analyses. Front Oncol 2021;11:688203. [PMID: 34249738 DOI: 10.3389/fonc.2021.688203] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Pei Y, Shi M, Song J, Niu X, Wei S, Dou L, Xiao M, Li D, Xu F, Bai Y, Sun K. Absolute Circulating Leukemic Cells as a Risk Factor for Early Bleeding Events in Patients with Non-High-Risk Acute Promyelocytic Leukemia. Cancer Manag Res 2021;13:4135-46. [PMID: 34045900 DOI: 10.2147/CMAR.S309138] [Reference Citation Analysis]
8 Zhao H, Sun J, Yan L, Jin B, Hou W, Cao F, Li H, Zhou J, Zhang Y. Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study. Ann Hematol 2021;100:1473-83. [PMID: 33893844 DOI: 10.1007/s00277-021-04533-9] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Kulkarni U, Mathews V. Evolving Chemotherapy Free Regimens for Acute Promyelocytic Leukemia. Front Oncol 2021;11:621566. [PMID: 33718181 DOI: 10.3389/fonc.2021.621566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ferro JM, Infante J. Cerebrovascular manifestations in hematological diseases: an update.J Neurol. 2021;268:3480-3492. [PMID: 33586004 DOI: 10.1007/s00415-021-10441-9] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Gurnari C, Voso MT, Girardi K, Mastronuzzi A, Strocchio L. Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy. Int J Mol Sci 2021;22:E642. [PMID: 33440683 DOI: 10.3390/ijms22020642] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]